Background
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research.• Herpes Simplex Virus 1 UL36USP Antagonizes Type I Interferon-Mediated Antiviral Innate Immunity., PMID:29997210• Structure-function study of the extracellular domain of the human type I interferon receptor (IFNAR)-1 subunit., PMID:10841076• The neutralization of type I IFN biologic actions by anti-IFNAR-2 monoclonal antibodies is not entirely due to inhibition of Jak-Stat tyrosine phosphorylation., PMID:11096454• ITAM-coupled receptors inhibit IFNAR signaling and alter macrophage responses to TLR4 and Listeria monocytogenes., PMID:22368279• Influence of type-I Interferon receptor expression level on the response to type-I Interferons in human pancreatic cancer cells., PMID:24460759• The receptor for type I IFNs is highly expressed on peripheral blood B cells and monocytes and mediates a distinct profile of differentiation and activation of these cells., PMID:14980077• N-glycosylation of murine IFN-beta in a putative receptor-binding region., PMID:16734561• Expression and function of RIG-I in oral keratinocytes and fibroblasts., PMID:25359319• Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis., PMID:21832278• Differential Responsiveness of Monocyte and Macrophage Subsets to Interferon., PMID:31390156